EmbeddingGemma 2: an open, lightweight multimodal embedding model
deepmind.google·6d ago
AI Engineering
Hacker News·Aug 24·5 min read
FDA clears blood test to aid evaluation for Alzheimer's disease
TL;DR
The FDA has approved PrecivityAD2, a blood test developed by C2N Diagnostics, for early diagnosis of Alzheimer's disease by detecting amyloid plaques. This less invasive method could enhance patient evaluation and treatment timing.
✦ Why It Matters
Consider using PrecivityAD2 for patient evaluations to enable earlier Alzheimer’s treatment.
Key Takeaways
- Explore the use of PrecivityAD2 for Alzheimer's diagnosis in clinical settings.
- Stay informed about new Alzheimer's treatments that benefit from early diagnosis.
- Consider the implications of blood-based tests for patient management strategies.
- Engage with healthcare professionals about innovative diagnostic tools.
Full Summary
PrecivityAD2 is a blood-based diagnostic test that helps identify amyloid plaques in the brain, which are linked to Alzheimer's disease. Developed by C2N Diagnostics, a startup from Washington University, this test utilizes high-resolution mass spectrometry to measure specific biomarkers in the blood, providing a less invasive alternative to cerebrospinal fluid tests.
With over 90% accuracy, it matches the effectiveness of more invasive methods like spinal taps and brain scans, even in patients with mild symptoms. The FDA's clearance allows for broader marketing and potential insurance coverage, making it more accessible to patients.
Early detection is crucial as new treatments for Alzheimer's are more effective when administered sooner.